Further analyses and longer follow-ups are needed. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.. focused on clinical features, diagnosis and outcome than on the radiological appearance, so we want to retrospectively report magnetic resonance imaging features of a group of eight patients, who came to our Ophthalmologic Emergency Department for optic neuritis and were found seropositive for myelin oligodendrocyte glycoprotein antibodies, comparing our data with the findings described in the literature. Keywords: Anti-myelin oligodendrocyte glycoprotein, demylinating disorders, magnetic resonance imaging, neuromyelitis optica, optic neuritis, recurrent optic neuritis Introduction Myelin oligodendrocyte glycoprotein (MOG) is a protein exclusively expressed on the surface of oligodendrocytes and myelin in the central nervous system, located on the outer surface of the myelin sheath.1,2 Antibodies (Abs) against MOG were initially detected in children with demyelinating syndromes3C10 and more recently reported in a broad spectrum of central nervous system demyelinating diseases in adults: in patients with aquaporin-4 (AQP4)-Abs-negative neuromyelitis optica spectrum disorder (NMOSD),11C17 in bilateral optic neuritis (ON),18 in isolated ON,19 in recurrent ON,20 clinically isolated syndrome (CIS),17 acute disseminated encephalomyelitis (ADEM),16,17 in patients with demyelinating diseases distinct from multiple sclerosis (MS) and neuromyelitis optica (NMO),21 and in patients with clinically defined MS according to the McDonald criteria.22C27 It has been hypothesised that the presence of anti-MOG Abs in distinct diseases may limit the use of Tyrosine kinase inhibitor the MOG-Abs assay as a specific diagnostic biomarker. Patients with MOG-Abs-associated demyelination appear to have unique clinical, radiological features and outcomes.26 The detection of the association between MOG-Abs and demyelinating disorders in adults is recent and in the literature we can find papers describing mainly clinical features, diagnosis and prognosis of patients with this type of antibody, with brief mention of radiological appearance but, to the best of our knowledge, no one reporting groups of Italian patients presenting with ON or focused on the radiologic aspects of this disorder, so we want to retrospectively report magnetic resonance imaging (MRI) features of a group of eight patients, who came to our Ophthalmologic Emergency Department for ON and were found seropositive for MOG-Abs, comparing our data with findings described in the literature. Material and methods Eight patients, (six females and two males, age range: 26C40 years; mean age: 32.8??5.7 years) came to our Ophthalmologic Emergency Tyrosine kinase inhibitor Department between February 2015CNovember 2016 complaining of ocular pain, worsened by eye movement (8/8), visual loss in one eye (5/8), visual field loss (3/5) diagnosed as ON (three of the left eye, four of the right eye and one recurrent bilateral ON, first left, afterwards right ON). All patients underwent ophthalmologic and neurological evaluation no comparison computed tomography (CT) scan of mind and orbits on the entrance, and MRI of mind, cervical spine and orbits in a period from 2C20 times following the onset of symptoms (mean times: 5.7??5.4). MRI Tyrosine kinase inhibitor of thoracolumbar backbone was executed with regards to the symptoms (1/8). CT scans had been carried out on Somatom Description Adobe flash (Siemens, Forchheim, Germany) with the next acquisition guidelines: kV:120, mAs: 320, collimation: 40??0.6?mm, pipe rotation: 1?s; reconstruction width: 3?mm; reconstruction filter systems: H21s soft for soft cells and H60 razor-sharp for bone tissue. All MRI examinations had been executed on the 1.5 T magnet (Avanto, Siemens, Forchheim, Germany), with sequences on the mind: sagittal T1 spin echo (SE) (thickness: 5?mm), axial proton density (PD) + T2 turbo spin echo (TSE) (thickness: 5?mm), diffusion weighted imaging with b ideals?=?0, 500, 1000?s/mm2 (thickness: 5?mm), axial T1 SE, coronal liquid attenuated inversion recovery (FLAIR) (thickness: 5?mm), sagittal dark liquid T2 space (thickness: 1?mm, with multiplanar reformation on axial and coronal planes); for the orbits: axial T2 TSE with body fat saturation (FS) (width: 3?mm), T2 brief tau inversion recovery (Mix) space (thickness: 1?mm, with multiplanar reformation on sagittal and coronal planes); for the backbone: sagittal T2 TSE (width: 4?mm), sagittal T1 TSE (thickness: 4?mm), sagittal T2 Mix. Gadolinium (1?ml/10?kg of gadobutrol, Gadovist, Bayer Schering Pharma) was administered to all or any individuals intravenously, prior to the acquisition of: axial and coronal T1 SE FS for the orbits (width: 3?mm), axial T1 SE Movement (thickness: 5?mm) and axial volumetric interpolated mind exam (VIBE) (width: 1?mm) about the mind, and sagittal T1 TSE FS for the backbone (thickness: 4?mm). All individuals were put through steroid therapy within 24 intravenously?h of their usage of the Emergency Division (methylprednisolone 1?g/d for five times, accompanied by a low-dose steroid dental routine for 15 times), therefore the CT was performed to CALNA therapy prior, however the MRI was performed following the begin of steroid treatment constantly. Based on the process established inside our Medical center in January 2014 for individuals with new starting point of unilateral or bilateral, recurrent or severe ON, suspected to become of demyelinating source, individuals underwent different investigations.